Keywords: Bayer, Drospirenone contraceptives, Yasmin, Yaz, Beyaz, Labeling, VTE risk, USA, FDA

Bayer updates drospirenone-containing COCs labels to reflect VTE risk

Article | 11 April 2012

Print This

Following a further review of the products by the US Food and Drug Administration , Bayer HealthCare Pharmaceuticals, a US unit ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in